Davis's Drug Guide
cosibelimab
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
Pronunciation:
koe-si-bel-i-mab
Trade Name(s)
- Unloxcyt
Ther. Class.
Pharm. Class.
monoclonal antibodies
programmed death ligand 1 (PD-L1) inhibitors
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., and Cynthia A. Sanoski. "Cosibelimab." Davis's Drug Guide, 20th ed., F.A. Davis Company, 2026. Medicine Central, im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580169/all/cosibelimab.
Vallerand AHA, Sanoski CAC. Cosibelimab. Davis's Drug Guide. F.A. Davis Company; 2026. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580169/all/cosibelimab. Accessed August 4, 2026.
Vallerand, A. H., & Sanoski, C. A. (2026). Cosibelimab. In Davis's Drug Guide (20th ed.). F.A. Davis Company. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580169/all/cosibelimab
Vallerand AHA, Sanoski CAC. Cosibelimab [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2026. [cited 2026 August 04]. Available from: https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580169/all/cosibelimab.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - cosibelimab
ID - 3580169
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
BT - Davis's Drug Guide
UR - https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580169/all/cosibelimab
PB - F.A. Davis Company
ET - 20
DB - Medicine Central
DP - Unbound Medicine
ER -
